How much revenue did Mezzion Pharma Co generate this year?
Mezzion Pharma Co has achieved a revenue of 31.72 B KRW this year.
Mezzion Pharma Co Revenue 2024
Mezzion Pharma Co Revenue
31.72 B KRW
Ticker
140410.KQ
ISIN
KR7140410002
In 2024, Mezzion Pharma Co's sales reached 31.72 B KRW, a 3.24% difference from the 30.73 B KRW sales recorded in the previous year.
The Mezzion Pharma Co Revenue history
| YEAR | REVENUE (undefined KRW) | GROSS MARGIN (%) |
|---|---|---|
| 2023 | 31.72 | 12,25 |
| 2022 | 30.73 | -1,02 |
| 2021 | 26.65 | 13,88 |
| 2020 | 28.63 | 25,98 |
| 2019 | 17.92 | 16,19 |
| 2018 | 19.09 | 16,96 |
| 2017 | 5.59 | 16,09 |
| 2016 | 8.75 | 56,72 |
| 2015 | 14.93 | 65,85 |
| 2014 | 4.86 | 50,28 |
| 2013 | 4.4 | 56,72 |
| 2012 | 8.59 | 74,30 |
| 2011 | 5.07 | 100,00 |
| 2010 | 24.25 | 16,02 |
| 2009 | 18.44 | 21,06 |
| 2008 | 0.21 | 1885,65 |
Mezzion Pharma Co Revenue, EBIT, Net Income KR7140410002 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Mezzion Pharma Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Mezzion Pharma Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Mezzion Pharma Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Mezzion Pharma Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Mezzion Pharma Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Mezzion Pharma Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Mezzion Pharma Co’s growth potential.
Mezzion Pharma Co Revenue, EBIT and net profit per share
| Date | Mezzion Pharma Co Revenue | Mezzion Pharma Co EBIT | Mezzion Pharma Co Net Income |
|---|---|---|---|
| 2023 | 31.72 B undefined | -14.49 B undefined | -12.73 B undefined |
| 2022 | 30.73 B undefined | -23.33 B undefined | -36.3 B undefined |
| 2021 | 26.65 B undefined | -16.8 B undefined | -13.6 B undefined |
| 2020 | 28.63 B undefined | -7.53 B undefined | -13.83 B undefined |
| 2019 | 17.92 B undefined | -24.72 B undefined | -23.25 B undefined |
| 2018 | 19.09 B undefined | -21.93 B undefined | -18.88 B undefined |
| 2017 | 5.59 B undefined | -16.85 B undefined | -14.88 B undefined |
| 2016 | 8.75 B undefined | -7.22 B undefined | -12.99 B undefined |
| 2015 | 14.93 B undefined | -2.73 B undefined | 4.22 B undefined |
| 2014 | 4.86 B undefined | -4.92 B undefined | -2.57 B undefined |
| 2013 | 4.4 B undefined | -2.47 B undefined | -831 M undefined |
| 2012 | 8.59 B undefined | 1.68 B undefined | 2.39 B undefined |
| 2011 | 5.07 B undefined | 2.93 B undefined | 3.2 B undefined |
| 2010 | 24.25 B undefined | 17.64 B undefined | 17.07 B undefined |
| 2009 | 18.44 B undefined | 12.97 B undefined | 11.57 B undefined |
| 2008 | 206 M undefined | -2.66 B undefined | -2.23 B undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2008 | 206 M KRW | -2.66 B KRW | -2.23 B KRW |
| 2009 | 18.44 B KRW | 12.97 B KRW | 11.57 B KRW |
| 2010 | 24.25 B KRW | 17.64 B KRW | 17.07 B KRW |
| 2011 | 5.07 B KRW | 2.93 B KRW | 3.2 B KRW |
| 2012 | 8.59 B KRW | 1.68 B KRW | 2.39 B KRW |
| 2013 | 4.4 B KRW | -2.47 B KRW | -831 M KRW |
| 2014 | 4.86 B KRW | -4.92 B KRW | -2.57 B KRW |
| 2015 | 14.93 B KRW | -2.73 B KRW | 4.22 B KRW |
| 2016 | 8.75 B KRW | -7.22 B KRW | -12.99 B KRW |
| 2017 | 5.59 B KRW | -16.85 B KRW | -14.88 B KRW |
| 2018 | 19.09 B KRW | -21.93 B KRW | -18.88 B KRW |
| 2019 | 17.92 B KRW | -24.72 B KRW | -23.25 B KRW |
| 2020 | 28.63 B KRW | -7.53 B KRW | -13.83 B KRW |
| 2021 | 26.65 B KRW | -16.8 B KRW | -13.6 B KRW |
| 2022 | 30.73 B KRW | -23.33 B KRW | -36.3 B KRW |
| 2023 | 31.72 B KRW | -14.49 B KRW | -12.73 B KRW |
Mezzion Pharma Co stock margins KR7140410002 ·
The Mezzion Pharma Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mezzion Pharma Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mezzion Pharma Co.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Mezzion Pharma Co's sales revenue. A higher gross margin percentage indicates that the Mezzion Pharma Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Mezzion Pharma Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Mezzion Pharma Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Mezzion Pharma Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Mezzion Pharma Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Mezzion Pharma Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Mezzion Pharma Co Margin History
| Mezzion Pharma Co Gross margin | Mezzion Pharma Co Profit margin | Mezzion Pharma Co EBIT margin | Mezzion Pharma Co Profit margin |
|---|---|---|---|
| 2023 | 12.25 % | -45.68 % | -40.13 % |
| 2022 | -1.02 % | -75.93 % | -118.13 % |
| 2021 | 13.88 % | -63.02 % | -51.03 % |
| 2020 | 25.98 % | -26.3 % | -48.3 % |
| 2019 | 16.19 % | -137.93 % | -129.75 % |
| 2018 | 16.96 % | -114.87 % | -98.89 % |
| 2017 | 16.09 % | -301.58 % | -266.42 % |
| 2016 | 56.72 % | -82.5 % | -148.38 % |
| 2015 | 65.85 % | -18.31 % | 28.29 % |
| 2014 | 50.28 % | -101.21 % | -52.87 % |
| 2013 | 56.72 % | -56.18 % | -18.88 % |
| 2012 | 74.3 % | 19.55 % | 27.76 % |
| 2011 | 100 % | 57.73 % | 63.23 % |
| 2010 | 12.25 % | 72.75 % | 70.4 % |
| 2009 | 12.25 % | 70.35 % | 62.73 % |
| 2008 | 12.25 % | -1,290.29 % | -1,082.04 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2008 | 12.25 % | -1,290.29 % | -1,082.04 % |
| 2009 | 12.25 % | 70.35 % | 62.73 % |
| 2010 | 12.25 % | 72.75 % | 70.4 % |
| 2011 | 100 % | 57.73 % | 63.23 % |
| 2012 | 74.3 % | 19.55 % | 27.76 % |
| 2013 | 56.72 % | -56.18 % | -18.88 % |
| 2014 | 50.28 % | -101.21 % | -52.87 % |
| 2015 | 65.85 % | -18.31 % | 28.29 % |
| 2016 | 56.72 % | -82.5 % | -148.38 % |
| 2017 | 16.09 % | -301.58 % | -266.42 % |
| 2018 | 16.96 % | -114.87 % | -98.89 % |
| 2019 | 16.19 % | -137.93 % | -129.75 % |
| 2020 | 25.98 % | -26.3 % | -48.3 % |
| 2021 | 13.88 % | -63.02 % | -51.03 % |
| 2022 | -1.02 % | -75.93 % | -118.13 % |
| 2023 | 12.25 % | -45.68 % | -40.13 % |
Mezzion Pharma Co Aktienanalyse
What does Mezzion Pharma Co do?
Mezzion Pharma Co Ltd is a biopharmaceutical company based in South Korea, focused on the development and commercialization of therapeutics for the treatment of heart diseases. The company was founded in 2009 and has been listed on the Korea Stock Exchange since 2014. Mezzion Pharma Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Mezzion Pharma Co's Sales Figures
The sales figures of Mezzion Pharma Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Mezzion Pharma Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Mezzion Pharma Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Mezzion Pharma Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Mezzion Pharma Co stock
How much was the turnover of the company Mezzion Pharma Co compared to the previous year?
The revenue of Mezzion Pharma Co has increased by 3.24% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Mezzion Pharma Co?
The revenue of Mezzion Pharma Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Mezzion Pharma Co measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Mezzion Pharma Co so important for investors?
The revenue of Mezzion Pharma Co is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Mezzion Pharma Co pay?
Over the past 12 months, Mezzion Pharma Co paid a dividend of 8.33 KRW . This corresponds to a dividend yield of about 0.03 %. For the coming 12 months, Mezzion Pharma Co is expected to pay a dividend of 0 KRW.
What is the dividend yield of Mezzion Pharma Co?
The current dividend yield of Mezzion Pharma Co is 0.03 %.
When does Mezzion Pharma Co pay dividends?
Mezzion Pharma Co pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Mezzion Pharma Co?
Mezzion Pharma Co paid dividends every year for the past 0 years.
What is the dividend of Mezzion Pharma Co?
For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.
In which sector is Mezzion Pharma Co located?
Mezzion Pharma Co is assigned to the 'Health' sector.
Wann musste ich die Aktien von Mezzion Pharma Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Mezzion Pharma Co from 4/1/2013 amounting to 25 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2012.
When did Mezzion Pharma Co pay the last dividend?
The last dividend was paid out on 4/1/2013.
What was the dividend of Mezzion Pharma Co in the year 2023?
In the year 2023, Mezzion Pharma Co distributed 0 KRW as dividends.
In which currency does Mezzion Pharma Co pay out the dividend?
The dividends of Mezzion Pharma Co are distributed in KRW.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Mezzion Pharma Co
Our stock analysis for Mezzion Pharma Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mezzion Pharma Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Mezzion Pharma Co Revenue
- Mezzion Pharma Co Net Income
- Mezzion Pharma Co P/E
- Mezzion Pharma Co P/S
- Mezzion Pharma Co EBIT
- Mezzion Pharma Co Dividend
- Mezzion Pharma Co Stocks
- Mezzion Pharma Co Market capitalization
- Mezzion Pharma Co Debt
- Mezzion Pharma Co Liabilities
- Mezzion Pharma Co Equity
- Mezzion Pharma Co AAQS
- Mezzion Pharma Co Employees
- Mezzion Pharma Co ROE
- Mezzion Pharma Co ROA
- Mezzion Pharma Co ROCE